{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:16:13Z","timestamp":1788401773732,"version":"build-2803163510"},"reference-count":477,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is a mostly sporadic brain disorder characterized by cognitive decline resulting from selective neurodegeneration in the hippocampus and cerebral cortex whereas Huntington\u2019s disease (HD) is a monogenic inherited disorder characterized by motor abnormalities and psychiatric disturbances resulting from selective neurodegeneration in the striatum. Although there have been numerous clinical trials for these diseases, they have been unsuccessful. Research conducted over the past three decades by a large number of laboratories has demonstrated that abnormal actions of common kinases play a key role in the pathogenesis of both AD and HD as well as several other neurodegenerative diseases. Prominent among these kinases are glycogen synthase kinase (GSK3), p38 mitogen-activated protein kinase (MAPK) and some of the cyclin-dependent kinases (CDKs). After a brief summary of the molecular and cell biology of AD and HD this review covers what is known about the role of these three groups of kinases in the brain and in the pathogenesis of the two neurodegenerative disorders. The potential of targeting GSK3, p38 MAPK and CDKS as effective therapeutics is also discussed as is a brief discussion on the utilization of recently developed drugs that simultaneously target two or all three of these groups of kinases. Multi-kinase inhibitors either by themselves or in combination with strategies currently being used such as immunotherapy or secretase inhibitors for AD and knockdown for HD could represent a more effective therapeutic approach for these fatal neurodegenerative diseases.<\/jats:p>","DOI":"10.3390\/ijms22115911","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T21:42:06Z","timestamp":1622497326000},"page":"5911","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["When Good Kinases Go Rogue: GSK3, p38 MAPK and CDKs as Therapeutic Targets for Alzheimer\u2019s and Huntington\u2019s Disease"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7652-1334","authenticated-orcid":false,"given":"Santosh R.","family":"D\u2019Mello","sequence":"first","affiliation":[{"name":"Neugeneron, Dallas, TX 75243, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"a011585","DOI":"10.1101\/cshperspect.a011585","article-title":"Alzheimer disease in 2020","volume":"2","author":"Holtzman","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-981-32-9358-8_16","article-title":"Amyloid-\u03b2 and Tau at the Crossroads of Alzheimer\u2019s Disease","volume":"1184","author":"Gallardo","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer Disease: An Update on Pathobiology and Treatment Strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/978-3-642-45106-5_14","article-title":"Huntington\u2019s disease","volume":"220","author":"Zuccato","year":"2014","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_8","first-page":"e12050","article-title":"Alzheimer\u2019s disease drug development pipeline: 2020","volume":"6","author":"Cummings","year":"2020","journal-title":"Alzheimers Dement."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-3-030-32633-3_15","article-title":"Alzheimer\u2019s Disease Therapeutic Approaches","volume":"1195","author":"Revi","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3233\/JHD-200002","article-title":"Huntington\u2019s Disease Clinical Trials Corner: April 2020","volume":"9","author":"Rodrigues","year":"2020","journal-title":"J. Huntingt. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.tig.2018.02.007","article-title":"Understanding Alzheimer Disease at the Interface between Genetics and Transcriptomics","volume":"34","author":"Verheijen","year":"2018","journal-title":"Trends Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/1567205012666141218140953","article-title":"Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer\u2019s disease","volume":"12","author":"Baranello","year":"2015","journal-title":"Curr. Alzheimer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1111\/bph.14593","article-title":"Targeting amyloid clearance in Alzheimer\u2019s disease as a therapeutic strategy","volume":"176","author":"Nalivaeva","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev-neuro-070815-014015","article-title":"Alzheimer\u2019s Disease Mechanisms and Emerging Roads to Novel Therapeutics","volume":"39","year":"2016","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrneurol.2015.225","article-title":"Tau and neurodegenerative disease: The story so far","volume":"12","author":"Iqbal","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2174\/1567205014666170417111859","article-title":"Tau in Alzheimer\u2019s Disease: Mechanisms and Therapeutic Strategies","volume":"15","author":"Gao","year":"2018","journal-title":"Curr. Alzheimer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1126\/science.1074069","article-title":"Alzheimer\u2019s disease is a synaptic failure","volume":"298","author":"Selkoe","year":"2002","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.neurobiolaging.2003.08.002","article-title":"Synaptic pathology in Alzheimer\u2019s disease: A review of ultrastructural studies","volume":"24","author":"Scheff","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.neurobiolaging.2005.09.012","article-title":"Hippocampal synaptic loss in early Alzheimer\u2019s disease and mild cognitive impairment","volume":"27","author":"Scheff","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3233\/JAD-122353","article-title":"Synapse stability in the precuneus early in the progression of Alzheimer\u2019s disease","volume":"35","author":"Scheff","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00702-010-0438-z","article-title":"Neuroinflammatory processes in Alzheimer\u2019s disease","volume":"117","author":"Heneka","year":"2010","journal-title":"J. Neural Transm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","article-title":"Neuroinflammation in Alzheimer\u2019s disease: Current evidence and future directions","volume":"12","author":"Calsolaro","year":"2016","journal-title":"Alzheimers Dement."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"952","DOI":"10.2174\/1567205013666160314150501","article-title":"Molecular Basis of Familial and Sporadic Alzheimer\u2019s Disease","volume":"13","author":"Dorszewska","year":"2016","journal-title":"Curr. Alzheimer Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Wolfe, C.M., Fitz, N.F., Nam, K.N., Lefterov, I., and Koldamova, R. (2018). The Role of APOE and TREM2 in Alzheimer\u2019s Disease-Current Understanding and Perspectives. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20010081"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.biopsych.2014.05.006","article-title":"Alzheimer\u2019s disease risk genes and mechanisms of disease pathogenesis","volume":"77","author":"Karch","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","article-title":"The Cellular Phase of Alzheimer\u2019s Disease","volume":"164","author":"Karran","year":"2016","journal-title":"Cell"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Kim, E., Otgontenger, U., Jamsranjav, A., and Kim, S.S. (2020). Deleterious Alteration of Glia in the Brain of Alzheimer\u2019s Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186676"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1001\/archneurol.2010.284","article-title":"Alzheimer\u2019s Disease Neuroimaging Initiative. Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative","volume":"67","author":"Carmichael","year":"2010","journal-title":"Arch. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3233\/JAD-131481","article-title":"Regional differences in white matter breakdown between frontotemporal dementia and early-onset Alzheimer\u2019s disease","volume":"39","author":"Lu","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.neurobiolaging.2003.03.001","article-title":"Age-related myelin breakdown: A developmental model of cognitive decline and Alzheimer\u2019s disease","volume":"25","author":"Bartzokis","year":"2004","journal-title":"Neurobiol. Aging"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.neurobiolaging.2009.08.007","article-title":"Alzheimer\u2019s disease as homeostatic responses to age-related myelin breakdown","volume":"32","author":"Bartzokis","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/glia.21131","article-title":"An Alzheimer\u2019s disease-relevant presenilin-1 mutation augments amyloid-beta-induced oligodendrocyte dysfunction","volume":"59","author":"Desai","year":"2011","journal-title":"Glia"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Narasimhan, S., Changolkar, L., Riddle, D.M., Kats, A., Stieber, A., Weitzman, S.A., Zhang, B., Li, Z., Roberson, E.D., and Trojanowski, J.Q. (2020). Human tau pathology transmits glial tau aggregates in the absence of neuronal tau. J. Exp. Med., 217.","DOI":"10.1084\/jem.20190783"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1080\/15384101.2015.1004937","article-title":"Neuronal cell cycle: The neuron itself and its circumstances","volume":"14","author":"Frade","year":"2015","journal-title":"Cell Cycle"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12640-011-9287-2","article-title":"Cell cycle proteins in brain in mild cognitive impairment: Insights into progression to Alzheimer disease","volume":"22","author":"Keeney","year":"2012","journal-title":"Neurotox. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e13109","DOI":"10.1111\/acel.13109","article-title":"\u201cAmyloid-beta accumulation cycle\u201d as a prevention and\/or therapy target for Alzheimer\u2019s disease","volume":"19","author":"Rao","year":"2020","journal-title":"Aging Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.2741\/e527","article-title":"The contributions of unscheduled neuronal cell cycle events to the death of neurons in Alzheimer\u2019s disease","volume":"4","author":"Herrup","year":"2012","journal-title":"Front. Biosci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s12640-011-9277-4","article-title":"Role of cell cycle re-entry in neurons: A common apoptotic mechanism of neuronal cell death","volume":"22","author":"Folch","year":"2012","journal-title":"Neurotox. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.neuint.2008.10.013","article-title":"Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer\u2019s disease","volume":"54","author":"Lee","year":"2009","journal-title":"Neurochem. Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0197-4580(01)00282-2","article-title":"Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer\u2019s disease neuropathology","volume":"23","author":"Xiang","year":"2002","journal-title":"Neurobiol. Aging"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3233\/JAD-2009-0993","article-title":"Activation of cell cycle proteins in transgenic mice in response to neuronal loss but not amyloid-beta and tau pathology","volume":"16","author":"Lopes","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11064-006-9123-x","article-title":"Regional expression of key cell cycle proteins in brain from subjects with amnestic mild cognitive impairment","volume":"32","author":"Sultana","year":"2007","journal-title":"Neurochem. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"140","DOI":"10.7150\/ijms.4.140","article-title":"BRCA1 may modulate neuronal cell cycle re-entry in Alzheimer disease","volume":"4","author":"Evans","year":"2007","journal-title":"Int. J. Med. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2353\/ajpath.2010.090955","article-title":"Selective cell death of hyperploid neurons in Alzheimer\u2019s disease","volume":"177","author":"Arendt","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.phrs.2016.02.007","article-title":"The antineoplastic drug flavopiridol reverses memory impairment induced by Amyloid-\u00df1-42 oligomers in mice","volume":"106","author":"Leggio","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1007\/s12035-020-01929-y","article-title":"Molecular Mechanisms of ER Stress and UPR in the Pathogenesis of Alzheimer\u2019s Disease","volume":"57","author":"Uddin","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nrneurol.2017.99","article-title":"ER stress and the unfolded protein response in neurodegeneration","volume":"13","author":"Hetz","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2174\/1567205015666181004143432","article-title":"The Implications of Autophagy in Alzheimer\u2019s Disease","volume":"15","author":"Hamano","year":"2018","journal-title":"Curr. Alzheimer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10571-016-0386-8","article-title":"Autophagy and Alzheimer\u2019s Disease","volume":"37","author":"Li","year":"2017","journal-title":"Cell Mol. Neurobiol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Reddy, P.H., and Oliver, D.M. (2019). Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer\u2019s Disease. Cells, 8.","DOI":"10.3390\/cells8050488"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fnagi.2018.00004","article-title":"Autophagy and Alzheimer\u2019s Disease: From Molecular Mechanisms to Therapeutic Implications","volume":"10","author":"Uddin","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"ref_53","first-page":"385","article-title":"Autophagy in Alzheimer\u2019s disease","volume":"26","author":"Masliah","year":"2015","journal-title":"Rev. Neurosci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3233\/JAD-170585","article-title":"Mitochondria and Mitochondrial Cascades in Alzheimer\u2019s Disease","volume":"62","author":"Swerdlow","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3233\/JAD-161088","article-title":"Oxidative Stress, Synaptic Dysfunction, and Alzheimer\u2019s Disease","volume":"57","author":"Trushina","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1177\/1535370220953065","article-title":"Overdosing on iron: Elevated iron and degenerative brain disorders","volume":"245","author":"Kindy","year":"2020","journal-title":"Exp. Biol. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/1568026619666191203113745","article-title":"Progress in Target Drug Molecules for Alzheimer\u2019s Disease","volume":"20","author":"Xie","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13195-017-0297-z","article-title":"Alzheimer\u2019s disease prevention: From risk factors to early intervention","volume":"9","author":"Gramunt","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s12264-019-00429-x","article-title":"Early Intervention in Alzheimer\u2019s Disease: How Early is Early Enough?","volume":"36","author":"Fan","year":"2020","journal-title":"Neurosci. Bull."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/joim.12959","article-title":"Current and emerging avenues for Alzheimer\u2019s disease drug targets","volume":"286","author":"Kenigsberg","year":"2019","journal-title":"J. Intern. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.npep.2015.06.008","article-title":"Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer\u2019s disease","volume":"52","author":"Barage","year":"2015","journal-title":"Neuropeptides"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1016\/j.febslet.2008.10.026","article-title":"The role of glycogen synthase kinase 3 in the early stages of Alzheimers\u2019 disease","volume":"582","author":"Avila","year":"2008","journal-title":"FEBS Lett."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"107","DOI":"10.55782\/ane-2004-1496","article-title":"Alzheimer\u2019s disease and the Cell Cycle","volume":"64","author":"Raina","year":"2004","journal-title":"Acta Neurobiol. Exp."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The Biology of Huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1111\/j.1460-9568.2008.06310.x","article-title":"Mechanisms of neurodegeneration in Huntington\u2019s disease","volume":"27","author":"Gil","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.pneurobio.2006.11.004","article-title":"Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington\u2019s disease","volume":"83","author":"Truant","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.conb.2020.04.001","article-title":"Traffic signaling: New functions of huntingtin and axonal transport in neurological disease","volume":"63","author":"Vitet","year":"2020","journal-title":"Curr. Opin. Neurobiol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Gao, R., Chakraborty, A., Geater, C., Pradhan, S., Gordon, K.L., Snowden, J., Yuan, S., Dickey, A.S., Choudhary, S., and Ashizawa, T. (2019). Mutant huntingtin impairs PNKP and ATXN3, disrupting DNA repair and transcription. Elife, 8.","DOI":"10.7554\/eLife.42988"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.tins.2014.09.003","article-title":"Autophagy in Huntington disease and huntingtin in Autophagy","volume":"38","author":"Martin","year":"2015","journal-title":"Trends Neurosci."},{"key":"ref_70","first-page":"672","article-title":"Mutant HTT (huntingtin) impairs mitophagy in a cellular model of Huntington disease","volume":"17","author":"Montpeyo","year":"2020","journal-title":"Autophagy"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"10034","DOI":"10.1523\/JNEUROSCI.0715-14.2014","article-title":"Mutant huntingtin affects cortical progenitor cell division and development of the mouse neocortex","volume":"34","author":"Barnat","year":"2014","journal-title":"J. Neurosci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bpa.12426","article-title":"Huntington\u2019s disease (HD): The neuropathology of a multisystem neurodegenerative disorder of the human Brain","volume":"26","author":"Seidel","year":"2016","journal-title":"Brain Pathol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"16017","DOI":"10.1074\/jbc.M111.252577","article-title":"Identification of novel potentially toxic oligomers formed in vitro from mammalian-derived expanded huntingtin exon-1 protein","volume":"287","author":"Nucifora","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1038\/ncomms3753","article-title":"Soluble forms of polyQ-expanded huntingtin rather than large aggregates cause endoplasmic reticulum stress","volume":"4","author":"Leitman","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.febslet.2015.05.041","article-title":"Prefibrillar huntingtin oligomers isolated from HD brain potently seed amyloid formation","volume":"589","author":"Morozova","year":"2015","journal-title":"FEBS Lett."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/mds.26331","article-title":"Therapeutic advances in Huntington\u2019s Disease","volume":"30","author":"Shannon","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.drudis.2014.02.006","article-title":"Mechanisms of synaptic dysfunction and excitotoxicity in Huntington\u2019s disease","volume":"19","author":"Sepers","year":"2014","journal-title":"Drug Discov. Today"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-3-319-71779-1_3","article-title":"Mitochondrial Dysfunction in Huntington\u2019s Disease","volume":"1049","author":"Carmo","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.tibs.2013.05.003","article-title":"Huntington\u2019s disease: Underlying molecular mechanisms and emerging concepts","volume":"38","author":"Labbadia","year":"2013","journal-title":"Trends Biochem. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/hmg\/ddt036","article-title":"A critical role of astrocyte-mediated nuclear factor-\u03baB-dependent inflammation in Huntington\u2019s disease","volume":"22","author":"Hsiao","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12035-009-8097-5","article-title":"Targeting glial cells to elucidate the pathogenesis of Huntington\u2019s disease","volume":"41","author":"Hsiao","year":"2010","journal-title":"Mol. Neurobiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"577380","DOI":"10.1016\/j.jneuroim.2020.577380","article-title":"Inflammation in Huntington\u2019s disease: A few new twists on an old tale","volume":"348","author":"Santos","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.brainresbull.2006.10.029","article-title":"Imaging microglial activation in Huntington\u2019s disease","volume":"72","author":"Tai","year":"2007","journal-title":"Brain Res. Bull."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/brain\/awm044","article-title":"Microglial activation in presymptomatic Huntington\u2019s disease gene carriers","volume":"130","author":"Tai","year":"2007","journal-title":"Brain"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease","volume":"205","author":"Wild","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1083\/jcb.200909067","article-title":"IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome","volume":"187","author":"Thompson","year":"2009","journal-title":"J. Cell Biol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.neuron.2009.11.020","article-title":"Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice","volume":"64","author":"Gu","year":"2009","journal-title":"Neuron"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"29427","DOI":"10.1074\/jbc.M109.013193","article-title":"Phosphorylation of Threonine 3: Implications for huntingtin aggregation and neurotoxicity","volume":"284","author":"Aiken","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nchembio.582","article-title":"Kinase inhibitors modulate huntingtin cell localization and toxicity","volume":"7","author":"Atwal","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.bbrc.2015.06.116","article-title":"Detection of huntingtin exon 1 phosphorylation by Phos-Tag SDS-PAGE: Predominant phosphorylation on threonine 3 and regulation by IKK\u03b2","volume":"463","author":"Bustamante","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Lontay, B., Kiss, A., Vir\u00e1g, L., and Tar, K. (2020). How Do Post-Translational Modifications Influence the Pathomechanistic Landscape of Huntington\u2019s Disease? A Comprehensive Review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124282"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Sawant, N., and Reddy, P.H. (2019). Role of Phosphorylated Tau and Glucose Synthase Kinase 3 Beta in Huntington\u2019s Disease Progression. J. Alzheimer Dis.","DOI":"10.3233\/JAD-190851"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/s41374-018-0166-9","article-title":"Spectrum of tau pathologies in Huntington\u2019s disease","volume":"99","author":"Baskota","year":"2019","journal-title":"Lab. Investig."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/jnc.13762","article-title":"Is there a role of Tau in Huntington\u2019s disease?","volume":"139","author":"Zerr","year":"2016","journal-title":"J. Neurochem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/brain\/awx255","article-title":"Presence of tau pathology within foetal neural allografts in patients with Huntington\u2019s and Parkinson\u2019s disease","volume":"140","author":"Cisbani","year":"2017","journal-title":"Brain"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/brain\/awv107","article-title":"REGISTRY Investigators of the European Huntington\u2019s Disease Network. The role of tau in the pathological process and clinical expression of Huntington\u2019s disease","volume":"138","author":"Vuono","year":"2015","journal-title":"Brain"},{"key":"ref_97","first-page":"574","article-title":"Altered Levels and Isoforms of Tau and Nuclear Membrane Invaginations in Huntington\u2019s Disease","volume":"13","author":"Lucas","year":"2019","journal-title":"Front. Cell Neurosci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/bpa.12430","article-title":"Faulty splicing and cytoskeleton abnormalities in Huntington\u2019s disease","volume":"26","author":"Cabrera","year":"2016","journal-title":"Brain Pathol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nm.3617","article-title":"Huntington\u2019s disease is a four-repeat tauopathy with tau nuclear rods","volume":"20","author":"Cabrera","year":"2014","journal-title":"Nat. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1179069518772380","DOI":"10.1177\/1179069518772380","article-title":"Tau: A Common Denominator and Therapeutic Target for Neurodegenerative Disorders","volume":"12","author":"Maxan","year":"2018","journal-title":"J. Exp. Neurosci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"580732","DOI":"10.3389\/fneur.2020.580732","article-title":"Targeting Tau to Treat Clinical Features of Huntington\u2019s Disease","volume":"11","author":"Masnata","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/brain\/aww021","article-title":"Is Huntington\u2019s disease a tauopathy?","volume":"139","author":"Gratuze","year":"2016","journal-title":"Brain"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1038\/s41598-017-05125-2","article-title":"A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington\u2019s disease mice","volume":"7","author":"Suelves","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Jia, H., Wang, Y., Morris, C.D., Jacques, V., Gottesfeld, J.M., Rusche, J.R., and Thomas, E.A. (2016). The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington\u2019s Disease Mice. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0152498"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.nbd.2012.01.016","article-title":"Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington\u2019s disease","volume":"46","author":"Jia","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1523\/JNEUROSCI.5704-10.2011","article-title":"Selective toxicity by HDAC3 in neurons: Regulation by Akt and GSK3beta","volume":"31","author":"Bardai","year":"2011","journal-title":"J. Neurosci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"11833","DOI":"10.1523\/JNEUROSCI.5831-12.2013","article-title":"Disassociation of histone deacetylase-3 from normal huntingtin underlies mutant huntingtin neurotoxicity","volume":"33","author":"Bardai","year":"2013","journal-title":"J. Neurosci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting Huntingtin Expression in Patients with Huntington\u2019s Disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/WCO.0000000000000835","article-title":"Therapeutic strategies for Huntington\u2019s disease","volume":"33","author":"Flower","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/mds.28397","article-title":"Targeting Expanded Repeats by Small Molecules in Repeat Expansion Disorders","volume":"36","author":"Nakamori","year":"2021","journal-title":"Mov. Disord."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41588-019-0575-8","article-title":"A slipped-CAG DNA-binding small molecule induces trinucleotide-repeat contractions in vivo","volume":"52","author":"Nakamori","year":"2020","journal-title":"Nat. Genet."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1432-1033.1980.tb06059.x","article-title":"Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase","volume":"107","author":"Embi","year":"1980","journal-title":"Eur. J. Biochem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0014-5793(79)80155-6","article-title":"Glycogen synthase kinase-2 from rabbit skeletal muscle is activated by the calcium-dependent regulator protein","volume":"98","author":"Rylatt","year":"1979","journal-title":"FEBS Lett."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1016\/S0021-9258(18)50694-3","article-title":"Purification and properties of cyclic AMP-independent glycogen synthase kinase 1 from rabbit skeletal muscle","volume":"254","author":"Itarte","year":"1979","journal-title":"J. Biol. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/j.1460-2075.1990.tb07419.x","article-title":"Molecular cloning and expression of glycogen synthase kinase-3\/factor A","volume":"9","author":"Woodgett","year":"1990","journal-title":"EMBO J."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"9643","DOI":"10.1074\/jbc.R800077200","article-title":"Unique and Overlapping Functions of GSK-3 Isoforms in Cell Differentiation and Proliferation and Cardiovascular Development","volume":"284","author":"Force","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1172\/JCI36245","article-title":"Deletion of GSK-3\u03b2 in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation","volume":"118","author":"Kerkela","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1172\/JCI64398","article-title":"GSK-3\u03b1 is a central regulator of age-related pathologies in mice","volume":"123","author":"Zhou","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e105513","DOI":"10.15252\/embj.2020105513","article-title":"GSK3\u03b1, not GSK3\u03b2, drives hippocampal NMDAR-dependent LTD via tau-mediated spine anchoring","volume":"40","author":"Draffin","year":"2021","journal-title":"EMBO J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/hipo.22362","article-title":"Dynamic range of GSK3\u03b1 not GSK3\u03b2 is essential for bidirectional synaptic plasticity at hippocampal CA3-CA1 synapses","volume":"24","author":"Shahab","year":"2014","journal-title":"Hippocampus"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1756-6606-2-35","article-title":"Abnormalities in brain structure and behavior in GSK-3alpha mutant mice","volume":"2","author":"Lipina","year":"2009","journal-title":"Mol. Brain"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.schres.2011.03.032","article-title":"Genetic inactivation of GSK3\u03b1 rescues spine deficits in Disc1-L100P mutant mice","volume":"129","author":"Lee","year":"2011","journal-title":"Schizophr. Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.11.016","article-title":"Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases","volume":"148","author":"Beurel","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/jnr.21932","article-title":"Calpain-mediated truncation of GSK-3 in post-mortem brain samples","volume":"87","author":"Avila","year":"2009","journal-title":"J. Neurosci. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neuint.2011.03.021","article-title":"Calpain regulates N-terminal interaction of GSK-3\u03b2 with 14-3-3\u03b6, p53 and PKB but not with axin","volume":"59","author":"Avila","year":"2011","journal-title":"Neurochem. Int."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"8187","DOI":"10.1038\/srep08187","article-title":"Truncation and activation of GSK-3\u03b2 by calpain I: A molecular mechanism links to tau hyperphosphorylation in Alzheimer\u2019s disease","volume":"5","author":"Jin","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"22406","DOI":"10.1074\/jbc.M702793200","article-title":"N-terminal cleavage of GSK-3 by calpain: A new form of GSK-3 regulation","volume":"282","author":"Lucas","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/cvr\/cvp175","article-title":"Glycogen synthase kinase-3beta is activated by matrix metalloproteinase-2 mediated proteolysis in cardiomyoblasts","volume":"83","author":"Kandasamy","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1478-811X-11-5","article-title":"ARTD10 substrate identification on protein microarrays: Regulation of GSK3\u03b2 by mono-ADP-ribosylation","volume":"11","author":"Feijs","year":"2013","journal-title":"Cell Commun. Signal."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nsmb.2521","article-title":"Macrodomain-containing proteins are new mono-ADP-ribosylhydrolases","volume":"20","author":"Rosenthal","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e32952","DOI":"10.7554\/eLife.32952","article-title":"SIRT2 deacetylase regulates the activity of GSK3 isoforms independent of inhibitory phosphorylation","volume":"7","author":"Sarikhani","year":"2018","journal-title":"Elife"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1096\/fj.12-220129","article-title":"Sirt1 inhibits the transcription factor CREB to regulate pituitary growth hormone synthesis","volume":"27","author":"Seoane","year":"2013","journal-title":"FASEB J."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1073\/pnas.1308362110","article-title":"Dysregulation of PAD4-mediated citrullination of nuclear GSK3\u03b2 activates TGF-\u03b2 signaling and induces epithelial-to-mesenchymal transition in breast cancer cells","volume":"110","author":"Stadler","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.neulet.2003.12.011","article-title":"Activation of the c-Jun transcription factor following neurodegeneration in vivo","volume":"361","author":"Schenkel","year":"2004","journal-title":"Neurosci. Lett."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0006-2952(00)00372-5","article-title":"c-Jun and the transcriptional control of neuronal apoptosis","volume":"60","author":"Ham","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1177\/1535370220928278","article-title":"Histone deacetylase-3: Friend and foe of the brain","volume":"245","year":"2020","journal-title":"Exp. Biol. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fncel.2015.00042","article-title":"HDAC4 as a potential therapeutic target in neurodegenerative diseases: A summary of recent achievements","volume":"9","author":"Mielcarek","year":"2015","journal-title":"Front. Cell Neurosci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-3-319-53889-1_14","article-title":"Epigenetic Mechanisms of Gene Regulation in Amyotrophic Lateral Sclerosis","volume":"978","author":"Franco","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.cell.2007.05.052","article-title":"Systematic discovery of in vivo phosphorylation networks","volume":"129","author":"Linding","year":"2007","journal-title":"Cell"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"505607","DOI":"10.4061\/2011\/505607","article-title":"What Are the bona fide GSK3 Substrates?","volume":"2011","author":"Sutherland","year":"2011","journal-title":"Int. J. Alzheimers Dis."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nrn2870","article-title":"GSK3 signalling in neural development","volume":"11","author":"Hur","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1021\/cn300110c","article-title":"Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo","volume":"3","author":"Palomo","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/s41591-019-0375-9","article-title":"Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer\u2019s disease","volume":"25","author":"Cafini","year":"2019","journal-title":"Nat. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/hipo.20805","article-title":"GSK3\u03b2 overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrus","volume":"21","author":"Perez","year":"2011","journal-title":"Hippocampus"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1046\/j.1471-4159.2002.01269.x","article-title":"Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments","volume":"83","author":"Borrell","year":"2002","journal-title":"J. Neurochem."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.neuron.2007.01.029","article-title":"LTP inhibits LTD in the hippocampus via regulation of GSK3beta","volume":"53","author":"Peineau","year":"2007","journal-title":"Neuron"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"S428","DOI":"10.1038\/bjp.2008.2","article-title":"The role of GSK-3 in synaptic plasticity","volume":"153","author":"Peineau","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fnmol.2012.00013","article-title":"A pivotal role of GSK-3 in synaptic plasticity","volume":"5","author":"Bradley","year":"2012","journal-title":"Front. Mol. Neurosci."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cellsig.2008.10.014","article-title":"Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity","volume":"21","author":"Yuskaitis","year":"2009","journal-title":"Cell Signal."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s11064-006-9128-5","article-title":"Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics","volume":"32","author":"Jope","year":"2007","journal-title":"Neurochem. Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"129753","DOI":"10.4061\/2011\/129753","article-title":"Glycogen synthase kinase-3\u03b2: A mediator of inflammation in Alzheimer\u2019s disease?","volume":"2011","author":"Koistinaho","year":"2011","journal-title":"Int. J. Alzheimers Dis."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.molbrainres.2005.03.004","article-title":"Inhibition of GSK3beta is a common event in neuroprotection by different survival factors","volume":"137","author":"Chin","year":"2005","journal-title":"Brain Res. Mol. Brain Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/cdd.2011.94","article-title":"Glycogen synthase kinase 3\u03b2 inhibitors protect hippocampal neurons from radiation-induced apoptosis by regulating MDM2-p53 pathway","volume":"19","author":"Thotala","year":"2012","journal-title":"Cell Death Differ."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejphar.2004.07.115","article-title":"Glycogen synthase kinase-3 inhibitors prevent caspase-dependent apoptosis induced by ethanol in cultured rat cortical neurons","volume":"499","author":"Takadera","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/emboj\/20.1.27","article-title":"Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice","volume":"20","author":"Lucas","year":"2001","journal-title":"EMBO J."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s004010100435","article-title":"The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer\u2019s disease","volume":"103","author":"Leroy","year":"2002","journal-title":"Acta Neuropathol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00401-002-0587-8","article-title":"Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer\u2019s disease, Pick\u2019s disease, progressive supranuclear palsy and corticobasal degeneration","volume":"104","author":"Ferrer","year":"2002","journal-title":"Acta Neuropathol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pharmthera.2012.07.001","article-title":"Tau as a therapeutic target in neurodegenerative disease","volume":"136","author":"Himmelstein","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0014-5793(01)02256-6","article-title":"Tau-tubulin kinase phosphorylates tau at Ser-208 and Ser-210, sites found in paired helical filament-tau","volume":"492","author":"Tomizawa","year":"2001","journal-title":"FEBS Lett."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"10741","DOI":"10.1523\/JNEUROSCI.1065-09.2009","article-title":"Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology","volume":"29","author":"Polydoro","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1523\/JNEUROSCI.5245-07.2008","article-title":"Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing","volume":"28","author":"Wen","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nature01640","article-title":"GSK-3alpha regulates production of Alzheimer\u2019s disease amyloid-beta peptides","volume":"423","author":"Phiel","year":"2003","journal-title":"Nature"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.bbrc.2003.11.014","article-title":"Divergent roles of GSK3 and CDK5 in APP processing","volume":"312","author":"Ryder","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.1021\/bi035627j","article-title":"Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing","volume":"43","author":"Su","year":"2004","journal-title":"Biochemistry"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1471-4159.2008.05760.x","article-title":"N-cadherin-based adhesion enhances Abeta release and decreases Abeta42\/40 ratio","volume":"108","author":"Uemura","year":"2009","journal-title":"J. Neurochem."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1471-4159.2012.07741.x","article-title":"Gain of function by phosphorylation in Presenilin 1-mediated regulation of insulin signaling","volume":"121","author":"Maesako","year":"2012","journal-title":"J. Neurochem."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.neuroscience.2010.12.017","article-title":"Effect of glycogen synthase kinase 3 \u03b2-mediated presenilin 1 phosphorylation on amyloid \u03b2 production is negatively regulated by insulin receptor cleavage","volume":"177","author":"Maesako","year":"2011","journal-title":"Neuroscience"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1017\/S1461145711000149","article-title":"Increased NF-\u03baB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer\u2019s disease","volume":"15","author":"Chen","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1172\/JCI64516","article-title":"Inhibition of GSK3\u03b2-mediated BACE1 expression reduces Alzheimer-associated phenotypes","volume":"123","author":"Ly","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0168-0102(98)00061-3","article-title":"Activation of tau protein kinase I\/glycogen synthase kinase-3beta by amyloid beta peptide (25\u201335) enhances phosphorylation of tau in hippocampal neurons","volume":"31","author":"Takashima","year":"1998","journal-title":"Neurosci. Res."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"40162","DOI":"10.1074\/jbc.M308243200","article-title":"\u03b2-Amyloid induces paired helical filament-like tau filaments in tissue culture","volume":"278","author":"Ferrari","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s11418-019-01318-3","article-title":"Cornel iridoid glycoside induces autophagy to protect against tau oligomer neurotoxicity induced by the activation of glycogen synthase kinase-3\u03b2","volume":"73","author":"Yang","year":"2019","journal-title":"J. Nat. Med."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1128\/MCB.00930-12","article-title":"Glycogen synthase kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the amyloid-\u03b2 precursor protein","volume":"32","author":"Parr","year":"2012","journal-title":"Mol. Cell Biol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.tibs.2016.10.009","article-title":"Stressed and Inflamed, Can GSK3 Be Blamed?","volume":"42","author":"Jope","year":"2017","journal-title":"Trends Biochem. Sci."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1460-9568.2006.05245.x","article-title":"Glycogen synthase kinase-3 inhibition is integral to long-term potentiation","volume":"25","author":"Hooper","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.nbd.2009.05.025","article-title":"A novel GSK-3beta inhibitor reduces Alzheimer\u2019s pathology and rescues neuronal loss in vivo","volume":"35","author":"Sereno","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.freeradbiomed.2013.11.014","article-title":"Antisense oligonucleotide against GSK-3\u03b2 in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease","volume":"67","author":"Farr","year":"2014","journal-title":"Free Radic. Biol. Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.bbamcr.2010.04.003","article-title":"Study of the in vivo phosphorylation of E2F1 on Ser403","volume":"1803","author":"Real","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1111\/j.1471-4159.2007.04686.x","article-title":"Apoptotic action of E2F1 requires glycogen synthase kinase 3-beta activity in PC12 Cells","volume":"102","author":"Espada","year":"2007","journal-title":"J. Neurochem."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"e2206","DOI":"10.1038\/cddis.2016.104","article-title":"GSK-3\u03b2-induced Tau pathology drives hippocampal neuronal cell death in Huntington\u2019s disease: Involvement of astrocyte-neuron interactions","volume":"7","author":"Tirolo","year":"2016","journal-title":"Cell Death Dis."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Falcicchia, C., Tozzi, F., Arancio, O., Watterson, D.M., and Origlia, N. (2020). Involvement of p38 MAPK in Synaptic Function and Dysfunction. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165624"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1515\/revneuro-2018-0008","article-title":"Role of p38\/MAPKs in Alzheimer\u2019s disease: Implications for amyloid beta toxicity targeted therapy","volume":"30","author":"Kheiri","year":"2018","journal-title":"Rev. Neurosci."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0197-4580(03)00126-X","article-title":"Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1 beta production","volume":"25","author":"Kim","year":"2004","journal-title":"Neurobiol. Aging"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2013.01.007","article-title":"PI3 k\/akt inhibition induces apoptosis through p38 activation in neurons","volume":"70","author":"Junyent","year":"2013","journal-title":"Pharmacol. Res."},{"key":"ref_185","first-page":"1401","article-title":"p38 mitogen-activated protein kinase gene silencing rescues rat hippocampal neurons from ketamine-induced apoptosis: An in vitro study","volume":"42","author":"Guo","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.biocel.2011.06.001","article-title":"Reactive oxygen species participate in the p38-mediated apoptosis induced by potassium deprivation and staurosporine in cerebellar granule neurons","volume":"43","year":"2011","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1242\/jcs.01655","article-title":"Evidence that phosphorylation of the microtubule-associated protein Tau by SAPK4\/p38delta at Thr50 promotes microtubule assembly","volume":"118","author":"Feijoo","year":"2005","journal-title":"J. Cell Sci."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0014-5793(97)00483-3","article-title":"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases","volume":"409","author":"Goedert","year":"1997","journal-title":"FEBS Lett."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13195-016-0221-y","article-title":"Selective suppression of the \u03b1 isoform of p38 MAPK rescues late-stage tau pathology","volume":"8","author":"Maphis","year":"2016","journal-title":"Alzheimer Res. Ther."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/onc.2010.442","article-title":"p38 phosphorylates Rb on Ser567 by a novel, cell cycle-independent mechanism that triggers Rb-Hdm2 interaction and apoptosis","volume":"30","author":"Delston","year":"2011","journal-title":"Oncogene"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/emboj\/18.6.1559","article-title":"Regulation of Rb and E2F by signal transduction cascades: Divergent effects of JNK1 and p38 kinases","volume":"18","author":"Wang","year":"1999","journal-title":"EMBO J."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.neurobiolaging.2018.06.006","article-title":"An isoform-selective p38\u03b1 mitogen-activated protein kinase inhibitor rescues early entorhinal cortex dysfunctions in a mouse model of Alzheimer\u2019s disease","volume":"70","author":"Rutigliano","year":"2018","journal-title":"Neurobiol. Aging"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1523\/JNEUROSCI.0204-08.2008","article-title":"Receptor for Advanced Glycation End Product-Dependent Activation of p38 Mitogen-Activated Protein Kinase Contributes to Amyloid-\u03b2-Mediated Cortical Synaptic Dysfunction","volume":"28","author":"Origlia","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1523\/JNEUROSCI.1633-03.2004","article-title":"Block of Long-Term Potentiation by Naturally Secreted and Synthetic Amyloid \u03b2-Peptide in Hippocampal Slices Is Mediated via Activation of the Kinases c-Jun N-Terminal Kinase, Cyclin-Dependent Kinase 5, and p38 Mitogen-Activated Protein Kinase as well as Metabotropic Glutamate Receptor Type 5","volume":"24","author":"Wang","year":"2004","journal-title":"J. Neurosci."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.nbd.2011.12.019","article-title":"P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease","volume":"45","author":"Culbert","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Yang, X., Zhang, H., Wu, J., Yin, L., Yan, L.-J., and Zhang, C. (2018). Humanin Attenuates NMDA-Induced Excitotoxicity by Inhibiting ROS-dependent JNK\/p38 MAPK Pathway. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19102982"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s12031-014-0398-0","article-title":"P38 MAPK inhibition protects against glutamate neurotoxicity and modifies NMDA and AMPA receptor subunit expression","volume":"55","author":"Camins","year":"2015","journal-title":"J. Mol. Neurosci."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1523\/JNEUROSCI.18-12-04451.1998","article-title":"\u03b2-Amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes","volume":"18","author":"McDonald","year":"1998","journal-title":"J. Neurosci."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1083\/jcb.201701049","article-title":"p38 MAPK inhibits autophagy and promotes microglial inflammatory responses by phosphorylating ULK1","volume":"217","author":"He","year":"2017","journal-title":"J. Cell Biol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"8648","DOI":"10.1096\/fj.201900363R","article-title":"MicroRNA-124 regulates the expression of p62\/p38 and promotes autophagy in the inflammatory pathogenesis of Parkinson\u2019s disease","volume":"33","author":"Yao","year":"2019","journal-title":"FASEB J."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.pharmthera.2005.09.005","article-title":"The cell cycle as a therapeutic target for Alzheimer\u2019s disease","volume":"111","author":"Neve","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jalz.2018.08.013","article-title":"CDT2-controlled cell cycle reentry regulates the pathogenesis of Alzheimer\u2019s disease","volume":"15","author":"Huang","year":"2019","journal-title":"Alzheimers Dement."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3233\/JAD-141083","article-title":"Distinct chronology of neuronal cell cycle re-entry and tau pathology in the 3xTg-AD mouse model and Alzheimer\u2019s disease patients","volume":"43","author":"Hradek","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.pneurobio.2013.06.002","article-title":"Impaired autophagy and APP processing in Alzheimer\u2019s disease: The potential role of Beclin 1 interactome","volume":"106\u2013107","author":"Salminen","year":"2013","journal-title":"Prog. Neurobiol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1093\/cercor\/bhv032","article-title":"Cdk5 is a New Rapid Synaptic Homeostasis Regulator Capable of Initiating the Early Alzheimer-Like Pathology","volume":"26","author":"Sheng","year":"2016","journal-title":"Cereb. Cortex."},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Song, W.-J., Son, M.-Y., Lee, H.-W., Seo, H., Kim, J.H., and Chung, S.-H. (2015). Enhancement of BACE1 Activity by p25\/Cdk5-Mediated Phosphorylation in Alzheimer\u2019s Disease. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0136950"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1006\/mcne.2002.1108","article-title":"Cyclin-dependent kinase-5\/p35 phosphorylates Presenilin 1 to regulate carboxy-terminal fragment stability","volume":"20","author":"Lau","year":"2002","journal-title":"Mol. Cell Neurosci."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1091\/mbc.e10-07-0654","article-title":"Nuclear envelope dispersion triggered by deregulated Cdk5 precedes neuronal death","volume":"22","author":"Chang","year":"2011","journal-title":"Mol. Biol. Cell"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fnmol.2014.00065","article-title":"Physiological and pathological phosphorylation of tau by Cdk5","volume":"7","author":"Kimura","year":"2014","journal-title":"Front. Mol. Neurosci."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.molcel.2010.05.009","article-title":"Negative regulation of Vps34 by Cdk mediated phosphorylation","volume":"38","author":"Furuya","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1080\/00207454.2019.1645142","article-title":"Cdk5: A main culprit in neurodegeneration","volume":"129","author":"Gupta","year":"2019","journal-title":"Int. J. Neurosci."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1523\/JNEUROSCI.5177-11.2012","article-title":"Cdk5\/p25-induced cytosolic PLA2-mediated lysophosphatidylcholine production regulates neuroinflammation and triggers neurodegeneration","volume":"32","author":"Sundaram","year":"2012","journal-title":"J. Neurosci."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/j.bbadis.2015.06.025","article-title":"Cdk5-mediated mitochondrial fission: A key player in dopaminergic toxicity in Huntington\u2019s disease","volume":"1852","author":"Cherubini","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"7899","DOI":"10.1523\/JNEUROSCI.1396-07.2007","article-title":"Dopaminergic signaling and striatal neurodegeneration in Huntington\u2019s disease","volume":"27","author":"Tang","year":"2007","journal-title":"J. Neurosci."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"10090","DOI":"10.1523\/JNEUROSCI.3237-08.2008","article-title":"Dopaminergic and Glutamatergic Signaling Crosstalk in Huntington\u2019s Disease Neurodegeneration: The Role of p25\/Cyclin-Dependent Kinase 5","volume":"28","author":"Paoletti","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.biopsych.2019.03.001","article-title":"Cyclin-Dependent Kinase 5 Dysfunction Contributes to Depressive-like Behaviors in Huntington\u2019s Disease by Altering the DARPP-32 Phosphorylation Status in the Nucleus Accumbens","volume":"86","author":"Brito","year":"2019","journal-title":"Biol. Psychiatry"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41419-019-1818-4","article-title":"Site-specific phosphorylation of Fbxw7 by Cdk5\/p25 and its resulting decreased stability are linked to glutamate-induced excitotoxicity","volume":"10","author":"Ko","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1038\/emboj.2008.195","article-title":"Cdk5 phosphorylates Cdh1 and modulates cyclin B1 stability in excitotoxicity","volume":"27","author":"Maestre","year":"2008","journal-title":"EMBO J."},{"key":"ref_219","doi-asserted-by":"crossref","unstructured":"Damri, O., Shemesh, N., and Agam, G. (2020). Is There Justification to Treat Neurodegenerative Disorders by Repurposing Drugs? The Case of Alzheimer\u2019s Disease, Lithium, and Autophagy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010189"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2147\/NDT.S75717","article-title":"Activation of mTOR: A culprit of Alzheimer\u2019s disease?","volume":"11","author":"Cai","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/acel.12057","article-title":"mTOR regulates tau phosphorylation and degradation: Implications for Alzheimer\u2019s disease and other tauopathies","volume":"12","author":"Caccamo","year":"2013","journal-title":"Aging Cell"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1586\/ern.10.40","article-title":"Role of glycogen synthase kinase-3 in Alzheimer\u2019s disease pathogenesis and glycogen synthase kinase-3 inhibitors","volume":"10","author":"Avila","year":"2010","journal-title":"Expert Rev. Neurother."},{"key":"ref_223","first-page":"46","article-title":"GSK-3\u03b2, a pivotal kinase in Alzheimer disease","volume":"7","author":"Jurado","year":"2014","journal-title":"Front. Mol. Neurosci."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3233\/JAD-2006-9S335","article-title":"GSK-3 is essential in the pathogenesis of Alzheimer\u2019s disease","volume":"9","author":"Takashima","year":"2006","journal-title":"J. Alzheimers Dis."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s40263-016-0380-1","article-title":"Therapeutic Mechanisms of Lithium in Bipolar Disorder: Recent Advances and Current Understanding","volume":"30","author":"Malhi","year":"2016","journal-title":"CNS Drugs"},{"key":"ref_226","first-page":"133","article-title":"Validating GSK3 as an in vivo target of lithium action","volume":"37","author":"Klein","year":"2009","journal-title":"Biochem. Soc. Trans."},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Nunes, M.A., Sch\u00f6we, N.M., Monteiro-Silva, K.C., Baraldi-Tornisielo, T., Souza, S.I.G., Balthazar, J., Albuquerque, M.S., Caetano, A.L., Viel, T.A., and Buck, H.S. (2015). Chronic Microdose Lithium Treatment Prevented Memory Loss and Neurohistopathological Changes in a Transgenic Mouse Model of Alzheimer\u2019s Disease. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0142267"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1523\/JNEUROSCI.4321-06.2007","article-title":"Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer\u2019s disease are associated with reduced amyloid precursor protein phosphorylation","volume":"27","author":"Rockenstein","year":"2007","journal-title":"J. Neurosci."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1073\/pnas.0500466102","article-title":"Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo","volume":"102","author":"Noble","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_230","doi-asserted-by":"crossref","unstructured":"Sofola, O., Kerr, F., Rogers, I., Killick, R., Augustin, H., Gandy, C., Allen, M.J., Hardy, J., Lovestone, S., and Partridge, L. (2010). Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer\u2019s disease. PLoS Genet., 6.","DOI":"10.1371\/journal.pgen.1001087"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/01.wnf.0000150871.52253.b7","article-title":"The syndrome of irreversible lithium-effectuated neurotoxicity","volume":"28","author":"Thampy","year":"2005","journal-title":"Clin. Neuropharmacol."},{"key":"ref_232","first-page":"112","article-title":"Lithium neurotoxicity","volume":"28","author":"Sheean","year":"1991","journal-title":"Clin. Exp. Neurol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40261-017-0598-9","article-title":"Lithium Toxicity in Older Adults: A Systematic Review of Case Reports","volume":"38","author":"Sun","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1039\/C7MT00203C","article-title":"From direct to indirect lithium targets: A comprehensive review of omics data","volume":"9","author":"Roux","year":"2017","journal-title":"Metallomics"},{"key":"ref_235","first-page":"5","article-title":"Inositol, lithium, and the Brain","volume":"35","author":"Agranoff","year":"2001","journal-title":"Psychopharmacol. Bull."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1192\/bjp.bp.110.080044","article-title":"Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: Randomised controlled trial","volume":"198","author":"Forlenza","year":"2011","journal-title":"Br. J. Psychiatry"},{"key":"ref_237","first-page":"104","article-title":"Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer\u2019s disease","volume":"10","author":"Nunes","year":"2013","journal-title":"Curr. Alzheimer Res."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/01.wad.0000155068.23937.9b","article-title":"Does lithium therapy protect against the onset of dementia?","volume":"19","author":"Dunn","year":"2005","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/archpsyc.65.11.1331","article-title":"Lithium treatment and risk of dementia","volume":"65","author":"Kessing","year":"2008","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/gps.1964","article-title":"A feasibility and tolerability study of lithium in Alzheimer\u2019s disease","volume":"23","author":"Macdonald","year":"2008","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_241","first-page":"205","article-title":"Treatment of Alzheimer\u2019s disease with the GSK-3 inhibitor tideglusib: A pilot study","volume":"33","author":"Steinwachs","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JAD-141959","article-title":"A phase II trial of tideglusib in Alzheimer\u2019s disease","volume":"45","author":"Lovestone","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"S547","DOI":"10.3233\/JAD-179934","article-title":"The Conundrum of GSK3 Inhibitors: Is it the Dawn of a New Beginning?","volume":"64","author":"Bhat","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/jnc.12203","article-title":"AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans","volume":"125","author":"Georgievska","year":"2013","journal-title":"J. Neurochem."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"118134","DOI":"10.1016\/j.lfs.2020.118134","article-title":"Combinatorial drug therapy in cancer\u2014New insights","volume":"258","author":"Bhatia","year":"2020","journal-title":"Life Sci."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nbt.2284","article-title":"Combinatorial drug therapy for cancer in the post-genomic era","volume":"30","author":"Banerji","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.3389\/fimmu.2018.01774","article-title":"Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy","volume":"9","author":"Yao","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"18045","DOI":"10.1038\/s41598-019-54557-5","article-title":"The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer\u2019s disease in rodents","volume":"9","author":"Griebel","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"45937","DOI":"10.1074\/jbc.M306268200","article-title":"Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418","volume":"278","author":"Bhat","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/sj.mp.4001483","article-title":"GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila","volume":"9","author":"Mudher","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/sj.bjp.0707471","article-title":"Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation","volume":"152","author":"Selenica","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00213-018-5108-0","article-title":"Chronic low dose of AM404 ameliorates the cognitive impairment and pathological features in hyperglycemic 3xTg-AD mice","volume":"236","author":"Huang","year":"2019","journal-title":"Psychopharmacology"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/hipo.20711","article-title":"Cannabinoids modulate hippocampal memory and plasticity","volume":"20","author":"Abush","year":"2010","journal-title":"Hippocampus"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1021\/acs.jmedchem.5b01550","article-title":"Discovery of Isonicotinamides as Highly Selective, Brain Penetrable, and Orally Active Glycogen Synthase Kinase-3 Inhibitors","volume":"59","author":"Luo","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.nbd.2008.10.007","article-title":"GSK3 inhibitors show benefits in an Alzheimer\u2019s disease (AD) model of neurodegeneration but adverse effects in control animals","volume":"33","author":"Hu","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/neup.12373","article-title":"SAMP8 mice as a neuropathological model of accelerated brain aging and dementia: Toshio Takeda\u2019s legacy and future directions","volume":"37","author":"Akiguchi","year":"2017","journal-title":"Neuropathology"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.mad.2005.07.008","article-title":"Hyperphosphorylation of microtubule-associated protein tau in senescence-accelerated mouse (SAM)","volume":"126","author":"Canudas","year":"2005","journal-title":"Mech. Ageing Dev."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/jnr.22184","article-title":"Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington\u2019s disease","volume":"88","author":"Valencia","year":"2010","journal-title":"J. Neurosci. Res."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1212\/01.WNL.0000065888.88988.6E","article-title":"Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis","volume":"60","author":"Rosas","year":"2003","journal-title":"Neurology"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.nlm.2012.01.004","article-title":"Behavioural state differentially engages septohippocampal cholinergic and GABAergic neurons in R6\/1 Huntington\u2019s disease mice","volume":"97","author":"Ransome","year":"2012","journal-title":"Neurobiol. Learn Mem."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"874387","DOI":"10.1155\/2012\/874387","article-title":"Hippocampal neurogenesis, cognitive deficits and affective disorder in Huntington\u2019s disease","volume":"2012","author":"Ransome","year":"2012","journal-title":"Neural Plast."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/jnnp.56.5.487","article-title":"Neuronal loss in the hippocampus in Huntington\u2019s disease: A comparison with HIV infection","volume":"56","author":"Spargo","year":"1993","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S1534-5807(02)00188-0","article-title":"The IGF-1\/Akt pathway is neuroprotective in Huntington\u2019s disease and involves Huntingtin phosphorylation by Akt","volume":"2","author":"Humbert","year":"2002","journal-title":"Dev. Cell"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fnmol.2012.00033","article-title":"AKT\/GSK3 signaling pathway and schizophrenia","volume":"5","author":"Emamian","year":"2012","journal-title":"Front. Mol. Neurosci."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bbr.2017.11.015","article-title":"Diabetes mellitus and Alzheimer\u2019s disease: GSK-3\u03b2 as a potential link","volume":"339","author":"Zhang","year":"2018","journal-title":"Behav. Brain Res."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"33791","DOI":"10.1074\/jbc.M204861200","article-title":"Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington\u2019s disease mutation","volume":"277","author":"Carmichael","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_267","doi-asserted-by":"crossref","unstructured":"Voisine, C., Varma, H., Walker, N., Bates, E.A., Stockwell, B.R., and Hart, A.C. (2007). Identification of potential therapeutic drugs for huntington\u2019s disease using Caenorhabditis elegans. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0000504"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0361-9230(03)00141-2","article-title":"Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington\u2019s disease mutation","volume":"61","author":"Wood","year":"2003","journal-title":"Brain Res. Bull."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1038\/npp.2011.128","article-title":"Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington\u2019s disease","volume":"36","author":"Chiu","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X17666181227165722","article-title":"Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences","volume":"17","author":"Romoli","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"ref_271","first-page":"313702","article-title":"Valproic Acid Neuroprotection in the 6-OHDA Model of Parkinson\u2019s Disease Is Possibly Related to Its Anti-Inflammatory and HDAC Inhibitory Properties","volume":"2015","author":"Ximenes","year":"2015","journal-title":"J. Neurodegener. Dis."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/hmg\/ddm294","article-title":"A rational mechanism for combination treatment of Huntington\u2019s disease using lithium and rapamycin","volume":"17","author":"Sarkar","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"5040","DOI":"10.1093\/hmg\/ddv224","article-title":"Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington\u2019s disease","volume":"24","author":"Miguez","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41419-017-0190-5","article-title":"Glycogen synthase protects neurons from cytotoxicity of mutant huntingtin by enhancing the autophagy flux","volume":"9","author":"Rai","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1128\/MMBR.00031-10","article-title":"Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases","volume":"75","author":"Cargnello","year":"2011","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.bbamcr.2007.03.010","article-title":"p38 MAP-kinases pathway regulation, function and role in human diseases","volume":"1773","author":"Cuenda","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0968-0004(00)01595-4","article-title":"p38 MAP kinases: Beyond the stress response","volume":"25","author":"Nebreda","year":"2000","journal-title":"Trends Biochem. Sci."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nri1865","article-title":"The many paths to p38 mitogen-activated protein kinase activation in the immune system","volume":"6","author":"Ashwell","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_279","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Lim\u00f3n, A., Joaquin, M., Caballero, M., Posas, F., and de Nadal, E. (2020). The p38 Pathway: From Biology to Cancer Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21061913"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.biochi.2006.06.003","article-title":"Role of MAPKs in development and differentiation: Lessons from knockout mice","volume":"88","author":"Aouadi","year":"2006","journal-title":"Biochimie"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.molmed.2009.06.005","article-title":"p38(MAPK): Stress responses from molecular mechanisms to therapeutics","volume":"15","author":"Coulthard","year":"2009","journal-title":"Trends Mol. Med."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.cr.7290257","article-title":"Activation and signaling of the p38 MAP kinase pathway","volume":"15","author":"Zarubin","year":"2005","journal-title":"Cell Res."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"570586","DOI":"10.3389\/fnmol.2020.570586","article-title":"Functions of p38 MAP Kinases in the Central Nervous System","volume":"13","author":"Asih","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.4161\/cc.4.9.2043","article-title":"Activating p38 MAPK: New tricks for an old kinase","volume":"4","author":"Mittelstadt","year":"2005","journal-title":"Cell Cycle"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/sj.emboj.7601668","article-title":"TAO kinases mediate activation of p38 in response to DNA damage","volume":"26","author":"Raman","year":"2007","journal-title":"EMBO J."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1038\/sj.onc.1210392","article-title":"Differential regulation and properties of MAPKs","volume":"26","author":"Raman","year":"2007","journal-title":"Oncogene"},{"key":"ref_287","first-page":"649079","article-title":"The Role of p38 MAPK and Its Substrates in Neuronal Plasticity and Neurodegenerative Disease","volume":"2012","author":"Eales","year":"2012","journal-title":"J. Signal Transduct."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1074\/jbc.M508298200","article-title":"Combined signaling through ERK, PI3K\/AKT, and RAC1\/p38 is required for met-triggered cortical neuron migration","volume":"281","author":"Segarra","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1523\/JNEUROSCI.21-15-05513.2001","article-title":"The p38 mitogen-activated protein kinase is involved in associative learning in rabbits","volume":"21","author":"Zhen","year":"2001","journal-title":"J. Neurosci."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s10517-017-3816-9","article-title":"p38 MAPK is Involved in Regulation of Epigenetic Mechanisms of Food Aversion Learning","volume":"163","author":"Grinkevich","year":"2017","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1038\/s41467-019-10830-9","article-title":"Astrocytic p38\u03b1 MAPK drives NMDA receptor-dependent long-term depression and modulates long-term memory","volume":"10","author":"Navarrete","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/80624","article-title":"Dual MAP kinase pathways mediate opposing forms of long-term plasticity at CA3-CA1 synapses","volume":"3","author":"Bolshakov","year":"2000","journal-title":"Nat. Neurosci."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1113\/jphysiol.2008.153122","article-title":"Co-activation of p38 mitogen-activated protein kinase and protein tyrosine phosphatase underlies metabotropic glutamate receptor-dependent long-term depression","volume":"586","author":"Moult","year":"2008","journal-title":"J. Physiol."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.neuron.2006.10.035","article-title":"AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss","volume":"52","author":"Hsieh","year":"2006","journal-title":"Neuron"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1523\/JNEUROSCI.1362-18.2018","article-title":"Temperoammonic Stimulation Depotentiates Schaffer Collateral LTP via p38 MAPK Downstream of Adenosine A1 Receptors","volume":"39","author":"Izumi","year":"2019","journal-title":"J. Neurosci."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/hipo.20383","article-title":"Long-term potentiation inhibition by low-level N-methyl-D-aspartate receptor activation involves calcineurin, nitric oxide, and p38 mitogen-activated protein kinase","volume":"18","author":"Izumi","year":"2008","journal-title":"Hippocampus"},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/cdd.2015.135","article-title":"c-Abl-p38\u03b1 signaling plays an important role in MPTP-induced neuronal death","volume":"23","author":"Wu","year":"2016","journal-title":"Cell Death Differ."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1750-1326-6-84","article-title":"Microglial p38\u03b1 MAPK is critical for LPS-induced neuron degeneration, through a mechanism involving TNF\u03b1","volume":"6","author":"Xing","year":"2011","journal-title":"Mol. Neurodegener."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"20451","DOI":"10.1074\/jbc.M311164200","article-title":"Phosphorylation of p38 MAPK induced by oxidative stress is linked to activation of both caspase-8-and-9-mediated apoptotic pathways in dopaminergic neurons","volume":"279","author":"Choi","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"554613","DOI":"10.3389\/fncel.2020.554613","article-title":"N-Acetylcysteine Rescues Hippocampal Oxidative Stress-Induced Neuronal Injury via Suppression of p38\/JNK Signaling in Depressed Rats","volume":"14","author":"Fan","year":"2020","journal-title":"Front. Cell Neurosci."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s12031-014-0372-x","article-title":"Inhibition of neuronal p38\u03b1, but not p38\u03b2 MAPK, provides neuroprotection against three different neurotoxic insults","volume":"55","author":"Xing","year":"2015","journal-title":"J. Mol. Neurosci."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nn1869","article-title":"Rho mediates calcium-dependent activation of p38alpha and subsequent excitotoxic cell death","volume":"10","author":"Semenova","year":"2007","journal-title":"Nat. Neurosci."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3389\/fphar.2017.00072","article-title":"Genetic and Pharmacological Inhibition of p38\u03b1 Improves Locomotor Recovery after Spinal Cord Injury","volume":"8","author":"Umezawa","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0306-4522(99)00100-1","article-title":"The P38 mitogen-activated protein kinase inhibitor SB203580 antagonizes the inhibitory effects of interleukin-1beta on long-term potentiation in the rat dentate gyrus in vitro","volume":"93","author":"Coogan","year":"1999","journal-title":"Neuroscience"},{"key":"ref_305","first-page":"67","article-title":"p38 MAPK and PI3K\/AKT Signalling Cascades inParkinson\u2019s Disease","volume":"4","author":"Jha","year":"2015","journal-title":"Int. J. Mol. Cell Med."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3233\/JAD-2001-3107","article-title":"Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer\u2019s disease brains at different stages of neurofibrillary degeneration","volume":"3","author":"Pei","year":"2001","journal-title":"J. Alzheimers Dis."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1046\/j.1471-4159.1999.0722053.x","article-title":"p38 kinase is activated in the Alzheimer\u2019s disease brain","volume":"72","author":"Hensley","year":"1999","journal-title":"J. Neurochem."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0891-5849(00)00494-9","article-title":"Redox-active iron mediates amyloid-beta toxicity","volume":"30","author":"Rottkamp","year":"2001","journal-title":"Free Radic. Biol. Med."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neuron.2010.08.023","article-title":"Regulation of tau pathology by the microglial fractalkine receptor","volume":"68","author":"Bhaskar","year":"2010","journal-title":"Neuron"},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1046\/j.1471-4159.2001.00597.x","article-title":"Activation of MKK6, an upstream activator of p38, in Alzheimer\u2019s disease","volume":"79","author":"Zhu","year":"2001","journal-title":"J. Neurochem."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1006\/nbdi.2002.0538","article-title":"Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: Involvement of the p38MAPK pathway","volume":"11","author":"Giovannini","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.neurobiolaging.2004.02.022","article-title":"Secreted beta-amyloid precursor protein activates microglia via JNK and p38-MAPK","volume":"26","author":"Bodles","year":"2005","journal-title":"Neurobiol. Aging"},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"23658","DOI":"10.1074\/jbc.M513646200","article-title":"MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease","volume":"281","author":"Culbert","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1742-2094-4-21","article-title":"A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer\u2019s disease mouse model","volume":"4","author":"Munoz","year":"2007","journal-title":"J. Neuroinflamm."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"40817","DOI":"10.18632\/oncotarget.17256","article-title":"Rapamycin regulates macrophage activation by inhibiting NLRP3 inflammasome-p38 MAPK-NF\u03baB pathways in autophagy- and p62-dependent manners","volume":"8","author":"Ko","year":"2017","journal-title":"Oncotarget"},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1126\/science.aah6205","article-title":"Site-specific phosphorylation of tau inhibits amyloid-\u03b2 toxicity in Alzheimer\u2019s mice","volume":"354","author":"Ittner","year":"2016","journal-title":"Science"},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00401-020-02191-1","article-title":"Reduction of advanced tau-mediated memory deficits by the MAP kinase p38\u03b3","volume":"140","author":"Ittner","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1471-4159.2006.04052.x","article-title":"Sequential phosphorylation of tau protein by cAMP-dependent protein kinase and SAPK4\/p38delta or JNK2 in the presence of heparin generates the AT100 epitope","volume":"99","author":"Yoshida","year":"2006","journal-title":"J. Neurochem."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0014-5793(02)02460-2","article-title":"Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact Cells","volume":"515","author":"Goedert","year":"2002","journal-title":"FEBS Lett."},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1021\/acschemneuro.5b00002","article-title":"Targeting human central nervous system protein kinases: An isoform selective p38\u03b1MAPK inhibitor that attenuates disease progression in Alzheimer\u2019s disease mouse models","volume":"6","author":"Roy","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12974-017-0845-2","article-title":"Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes","volume":"14","author":"Zhou","year":"2017","journal-title":"J. Neuroinflamm."},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3233\/JAD-150277","article-title":"Selective Brain-Targeted Antagonism of p38 MAPK\u03b1 Reduces Hippocampal IL-1\u03b2 Levels and Improves Morris Water Maze Performance in Aged Rats","volume":"48","author":"Alam","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13195-020-00617-2","article-title":"A selective p38\u03b1\/\u03b2 MAPK inhibitor alleviates neuropathology and cognitive impairment, and modulates microglia function in 5XFAD mouse","volume":"12","author":"Gee","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/bcpt.12000","article-title":"Reduction of hippocampal apoptosis by intracerebroventricular administration of extracellular signal-regulated protein kinase and\/or p38 inhibitors in amyloid beta rat model of Alzheimer\u2019s disease: Involvement of nuclear-related factor-2 and nuclear factor-\u03baB","volume":"112","author":"Ashabi","year":"2013","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2174\/156720501303160217122803","article-title":"Triptolide Rescues Spatial Memory Deficits and Amyloid-\u03b2 Aggregation Accompanied by Inhibition of Inflammatory Responses and MAPKs Activity in APP\/PS1 Transgenic Mice","volume":"13","author":"Cui","year":"2016","journal-title":"Curr. Alzheimer Res."},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.3389\/fimmu.2019.02707","article-title":"Intranasal MMI-0100 Attenuates A\u03b21-42- and LPS-Induced Neuroinflammation and Memory Impairments via the MK2 Signaling Pathway","volume":"10","author":"Jiang","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_327","doi-asserted-by":"crossref","unstructured":"Muraleva, N.A., Stefanova, N.A., and Kolosova, N.G. (2020). SkQ1 Suppresses the p38 MAPK Signaling Pathway Involved in Alzheimer\u2019s Disease-Like Pathology in OXYS Rats. Antioxidants, 9.","DOI":"10.3390\/antiox9080676"},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1021\/acschemneuro.9b00271","article-title":"1-Trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) Urea, a Selective and Potent Dual Inhibitor of Soluble Epoxide Hydrolase and p38 Kinase Intervenes in Alzheimer\u2019s Signaling in Human Nerve Cells","volume":"10","author":"Liang","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3233\/JAD-190640","article-title":"Vitegnoside Mitigates Neuronal Injury, Mitochondrial Apoptosis, and Inflammation in an Alzheimer\u2019s Disease Cell Model via the p38 MAPK\/JNK Pathway","volume":"72","author":"Wang","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"108586","DOI":"10.1016\/j.steroids.2020.108586","article-title":"Active form of vitamin D analogue mitigates neurodegenerative changes in Alzheimer\u2019s disease in rats by targeting Keap1\/Nrf2 and MAPK-38p\/ERK signaling pathways","volume":"156","author":"Rashed","year":"2020","journal-title":"Steroids"},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.neuint.2019.01.021","article-title":"Novel compound VB-037 inhibits A\u03b2 aggregation and promotes neurite outgrowth through enhancement of HSP27 and reduction of P38 and JNK-mediated inflammation in cell models for Alzheimer\u2019s disease","volume":"125","author":"Chiu","year":"2019","journal-title":"Neurochem. Int."},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.2217\/nnm-2018-0496","article-title":"Inhibition of p38 MAPK in the brain through nasal administration of p38 inhibitor loaded in chitosan nanocapsules","volume":"14","author":"Matteis","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.nbd.2004.05.008","article-title":"Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow","volume":"17","author":"Gianfriddo","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.0953-816X.2003.03131.x","article-title":"The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin","volume":"19","author":"Rangone","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00018-010-0305-y","article-title":"Downregulation of NF-kappaB signaling by mutant huntingtin proteins induces oxidative stress and cell death","volume":"67","author":"Reijonen","year":"2010","journal-title":"Cell Mol. Life Sci."},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1523\/JNEUROSCI.4965-11.2013","article-title":"MAP kinase phosphatase 1 (MKP-1\/DUSP1) is neuroprotective in Huntington\u2019s disease via additive effects of JNK and p38 inhibition","volume":"33","author":"Taylor","year":"2013","journal-title":"J. Neurosci."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/jnc.12700","article-title":"Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington\u2019s disease mouse model","volume":"130","author":"Gladding","year":"2014","journal-title":"J. Neurochem."},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1523\/JNEUROSCI.3706-05.2006","article-title":"Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421","volume":"26","author":"Pardo","year":"2006","journal-title":"J. Neurosci."},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1172\/JCI80339","article-title":"Serine 421 regulates mutant huntingtin toxicity and clearance in mice","volume":"126","author":"Kratter","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_340","doi-asserted-by":"crossref","unstructured":"Huang, Z.-N., Chen, J.-M., Huang, L.-C., Fang, Y.-H., and Her, L.-S. (2021). Inhibition of p38 Mitogen-Activated Protein Kinase Ameliorates HAP40 Depletion-Induced Toxicity and Proteasomal Defect in Huntington\u2019s Disease Model. Mol. Neurobiol.","DOI":"10.1007\/s12035-020-02280-y"},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.nbd.2014.08.013","article-title":"Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington\u2019s disease","volume":"71","author":"Ferrante","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s10555-020-09885-8","article-title":"CDK7 inhibitors as anticancer drugs","volume":"39","author":"Sava","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-2957-3_1","article-title":"Cell Cycle Control: A System of Interlinking Oscillators","volume":"1342","author":"Poon","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"ref_344","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.tcb.2013.03.002","article-title":"Cell cycle control across the eukaryotic kingdom","volume":"23","author":"Harashima","year":"2013","journal-title":"Trends Cell Biol."},{"key":"ref_345","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/ncb1109-1275","article-title":"Cyclin-dependent kinases: A family portrait","volume":"11","author":"Malumbres","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"ref_346","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1242\/dev.091744","article-title":"Cdks, cyclins and CKIs: Roles beyond cell cycle regulation","volume":"140","author":"Lim","year":"2013","journal-title":"Development"},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s004410100396","article-title":"Neuronal apoptosis at the G1\/S cell cycle checkpoint","volume":"305","author":"Liu","year":"2001","journal-title":"Cell Tissue Res."},{"key":"ref_348","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2003.12.005","article-title":"Cell cycle regulation of neuronal apoptosis in development and disease","volume":"72","author":"Becker","year":"2004","journal-title":"Prog. Neurobiol."},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1365-2990.2010.01064.x","article-title":"Review: Cell cycle aberrations and neurodegeneration","volume":"36","author":"Bonda","year":"2010","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_350","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/s41419-018-1156-y","article-title":"Comparing effects of CDK inhibition and E2F1\/2 ablation on neuronal cell death pathways in vitro and after traumatic brain injury","volume":"9","author":"Aubrecht","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_351","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/jcb.20574","article-title":"E2F1 induces cell death, calpain activation, and MDMX degradation in a transcription independent manner implicating a novel role for E2F1 in neuronal loss in SIV encephalitis","volume":"96","author":"Strachan","year":"2005","journal-title":"J. Cell Biochem."},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1080\/15384101.2017.1361070","article-title":"E2f1 mediates high glucose-induced neuronal death in cultured mouse retinal explants","volume":"16","author":"Wang","year":"2017","journal-title":"Cell Cycle"},{"key":"ref_353","doi-asserted-by":"crossref","unstructured":"Wu, J., Kharebava, G., Piao, C., Stoica, B.A., Dinizo, M., Sabirzhanov, B., Hanscom, M., Guanciale, K., and Faden, A.I. (2012). Inhibition of E2F1\/CDK1 pathway attenuates neuronal apoptosis in vitro and confers neuroprotection after spinal cord injury in vivo. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0042129"},{"key":"ref_354","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1007\/s12035-020-01887-5","article-title":"Context-Dependent Functions of E2F1: Cell Cycle, Cell Death, and DNA Damage Repair in Cortical Neurons","volume":"57","author":"Zhang","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"ref_355","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.biopha.2006.11.001","article-title":"Implication of the transcription factor E2F-1 in the modulation of neuronal apoptosis","volume":"61","author":"Verdaguer","year":"2007","journal-title":"Biomed. Pharmacother."},{"key":"ref_356","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.neuropharm.2007.05.012","article-title":"Glycogen synthase kinase-3 is involved in the regulation of the cell cycle in cerebellar granule Cells","volume":"53","author":"Folch","year":"2007","journal-title":"Neuropharmacology"},{"key":"ref_357","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1146\/annurev-cellbio-092910-154023","article-title":"Cyclin-dependent kinases in brain development and disease","volume":"27","author":"Su","year":"2011","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_358","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/gtc.12029","article-title":"Extra-cell cycle regulatory functions of cyclin-dependent kinases (CDK) and CDK inhibitor proteins contribute to brain development and neurological disorders","volume":"18","author":"Kawauchi","year":"2013","journal-title":"Genes Cells"},{"key":"ref_359","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s12015-013-9460-5","article-title":"Cell cycle regulation during neurogenesis in the embryonic and adult Brain","volume":"9","author":"Cheffer","year":"2013","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_360","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1007\/s00018-020-03548-1","article-title":"Core cell cycle machinery is crucially involved in both life and death of post-mitotic neurons","volume":"77","author":"Marlier","year":"2020","journal-title":"Cell Mol. Life Sci."},{"key":"ref_361","doi-asserted-by":"crossref","unstructured":"Namba, T., and Huttner, W.B. (2017). Neural progenitor cells and their role in the development and evolutionary expansion of the neocortex. Wiley Interdiscip. Rev. Dev. Biol.","DOI":"10.1002\/wdev.256"},{"key":"ref_362","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.neuron.2020.11.014","article-title":"Metabolic Regulation of Neocortical Expansion in Development and Evolution","volume":"109","author":"Namba","year":"2020","journal-title":"Neuron"},{"key":"ref_363","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3389\/fncel.2019.00305","article-title":"Malformations of Human Neocortex in Development\u2014Their Progenitor Cell Basis and Experimental Model Systems","volume":"13","author":"Pinson","year":"2019","journal-title":"Front. Cell Neurosci."},{"key":"ref_364","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/j.1460-9568.2009.06661.x","article-title":"A putative role for cell cycle-related proteins in microtubule-based neuroplasticity","volume":"29","author":"Schmetsdorf","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"ref_365","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.neuron.2008.10.015","article-title":"Deregulation of HDAC1 by p25\/Cdk5 in neurotoxicity","volume":"60","author":"Kim","year":"2008","journal-title":"Neuron"},{"key":"ref_366","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ceb.2013.08.001","article-title":"Post-mitotic role of the cell cycle machinery","volume":"25","author":"Herrup","year":"2013","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_367","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12031-012-9716-6","article-title":"Stable mutated tau441 transfected SH-SY5Y cells as screening tool for Alzheimer\u2019s disease drug candidates","volume":"47","author":"Flunkert","year":"2012","journal-title":"J. Mol. Neurosci."},{"key":"ref_368","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2009.05.001","article-title":"Recent advances in understanding the roles of Cdk5 in synaptic plasticity","volume":"1792","author":"Lai","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_369","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1471-4159.2006.04040.x","article-title":"Cyclin-dependent kinase 5 in synaptic plasticity, learning and memory","volume":"99","author":"Angelo","year":"2006","journal-title":"J. Neurochem."},{"key":"ref_370","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1471-4159.2003.02328.x","article-title":"Cyclin-dependent kinase-5 in neurodegeneration","volume":"88","author":"Shelton","year":"2004","journal-title":"J. Neurochem."},{"key":"ref_371","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.neuron.2008.11.020","article-title":"A sequel to the tale of p25\/Cdk5 in neurodegeneration","volume":"60","author":"Ikiz","year":"2008","journal-title":"Neuron"},{"key":"ref_372","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1358\/dnp.2006.19.8.1043961","article-title":"The role of CDK5\/P25 formation\/inhibition in neurodegeneration","volume":"19","author":"Camins","year":"2006","journal-title":"Drug News Perspect."},{"key":"ref_373","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.devcel.2011.08.009","article-title":"Cyclin E constrains Cdk5 activity to regulate synaptic plasticity and memory formation","volume":"21","author":"Odajima","year":"2011","journal-title":"Dev. Cell"},{"key":"ref_374","doi-asserted-by":"crossref","first-page":"10786","DOI":"10.1523\/JNEUROSCI.2441-08.2008","article-title":"Abeta oligomers induce neuronal cell cycle events in Alzheimer\u2019s disease","volume":"28","author":"Varvel","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_375","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.brainres.2008.04.050","article-title":"Different fibrillar Abeta 1-42 concentrations induce adult hippocampal neurons to reenter various phases of the Cell Cycle","volume":"1218","author":"Majd","year":"2008","journal-title":"Brain Res."},{"key":"ref_376","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1750-1326-4-14","article-title":"The PI3K-Akt-mTOR pathway regulates Abeta oligomer induced neuronal cell cycle events","volume":"4","author":"Bhaskar","year":"2009","journal-title":"Mol. Neurodegener."},{"key":"ref_377","first-page":"5124","article-title":"Deregulated Cdk5 triggers aberrant activation of cell cycle kinases and phosphatases inducing neuronal death","volume":"125","author":"Chang","year":"2012","journal-title":"J. Cell Sci."},{"key":"ref_378","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1006\/exnr.1994.1057","article-title":"Microtubule-associated protein tau is hyperphosphorylated during mitosis in the human neuroblastoma cell line SH-SY5Y","volume":"126","author":"Pope","year":"1994","journal-title":"Exp. Neurol."},{"key":"ref_379","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1016\/S0021-9258(17)42989-9","article-title":"Phosphorylation affects the ability of tau protein to promote microtubule assembly","volume":"259","author":"Lindwall","year":"1984","journal-title":"J. Biol. Chem."},{"key":"ref_380","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.mad.2005.03.024","article-title":"The cell cycle in Alzheimer disease: A unique target for neuropharmacology","volume":"126","author":"Webber","year":"2005","journal-title":"Mech. Ageing Dev."},{"key":"ref_381","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1242\/jcs.1125880","article-title":"Amyloid-\u03b2 signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer\u2019s disease","volume":"126","author":"Seward","year":"2013","journal-title":"J. Cell Sci."},{"key":"ref_382","doi-asserted-by":"crossref","first-page":"9232","DOI":"10.1523\/JNEUROSCI.3347-04.2004","article-title":"Divide and die: Cell cycle events as triggers of nerve cell death","volume":"24","author":"Herrup","year":"2004","journal-title":"J. Neurosci."},{"key":"ref_383","doi-asserted-by":"crossref","first-page":"846","DOI":"10.18632\/aging.100382","article-title":"Inhibition of Polo-like kinase 1 reduces beta-amyloid-induced neuronal cell death in Alzheimer\u2019s disease","volume":"3","author":"Song","year":"2011","journal-title":"Aging"},{"key":"ref_384","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0197-4580(00)00219-0","article-title":"Beta-amyloid activated microglia induce cell cycling and cell death in cultured cortical neurons","volume":"21","author":"Wu","year":"2000","journal-title":"Neurobiol. Aging"},{"key":"ref_385","first-page":"731","article-title":"The cell division cycle and the pathophysiology of Alzheimer\u2019s disease","volume":"87","author":"Nagy","year":"1998","journal-title":"Neuroscience"},{"key":"ref_386","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s004010050665","article-title":"Cell cycle markers in the hippocampus in Alzheimer\u2019s disease","volume":"94","author":"Nagy","year":"1997","journal-title":"Acta Neuropathol."},{"key":"ref_387","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1523\/JNEUROSCI.21-08-02661.2001","article-title":"DNA replication precedes neuronal cell death in Alzheimer\u2019s disease","volume":"21","author":"Yang","year":"2001","journal-title":"J. Neurosci."},{"key":"ref_388","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1523\/JNEUROSCI.23-07-02557.2003","article-title":"Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer\u2019s disease","volume":"23","author":"Yang","year":"2003","journal-title":"J. Neurosci."},{"key":"ref_389","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3233\/JAD-2001-3205","article-title":"Constitutive Wee1 activity in adult brain neurons with M phase-type alterations in Alzheimer neurodegeneration","volume":"3","author":"Tomashevski","year":"2001","journal-title":"J. Alzheimers Dis."},{"key":"ref_390","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/S0002-9440(10)64837-7","article-title":"The cell cycle Cdc25A tyrosine phosphatase is activated in degenerating postmitotic neurons in Alzheimer\u2019s disease","volume":"157","author":"Ding","year":"2000","journal-title":"Am. J. Pathol."},{"key":"ref_391","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/0-387-23226-5_20","article-title":"Phosphorylated amyloid-beta: The toxic intermediate in alzheimer\u2019s disease neurodegeneration","volume":"38","author":"Milton","year":"2005","journal-title":"Subcell Biochem."},{"key":"ref_392","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00401-016-1546-0","article-title":"Phosphorylation of the amyloid \u03b2-peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity","volume":"131","author":"Kumar","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_393","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1021\/jm800109e","article-title":"Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1","volume":"51","author":"Oumata","year":"2008","journal-title":"J. Med Chem."},{"key":"ref_394","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0014-5793(93)80849-P","article-title":"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5","volume":"336","author":"Baumann","year":"1993","journal-title":"FEBS Lett."},{"key":"ref_395","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.jmb.2016.03.009","article-title":"Molecular Mechanism of Pin1-Tau Recognition and Catalysis","volume":"428","author":"Eichner","year":"2016","journal-title":"J. Mol. Biol."},{"key":"ref_396","doi-asserted-by":"crossref","unstructured":"Holzer, M., Schade, N., Opitz, A., Hilbrich, I., Stieler, J., Vogel, T., Neukel, V., Oberstadt, M., Totzke, F., and Sch\u00e4chtele, C. (2018). Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay. Molecules, 23.","DOI":"10.3390\/molecules23092335"},{"key":"ref_397","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3389\/fnmol.2017.00229","article-title":"Amyloid \u03b21-42 (A\u03b21-42) Induces the CDK2-Mediated Phosphorylation of Tau through the Activation of the mTORC1 Signaling Pathway While Promoting Neuronal Cell Death","volume":"10","author":"Lee","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"ref_398","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/35012636","article-title":"Neurotoxicity induces cleavage of p35 to p25 by calpain","volume":"405","author":"Lee","year":"2000","journal-title":"Nature"},{"key":"ref_399","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.molmed.2004.07.001","article-title":"Cdk5 deregulation in the pathogenesis of Alzheimer\u2019s disease","volume":"10","author":"Cruz","year":"2004","journal-title":"Trends Mol. Med."},{"key":"ref_400","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0896-6273(03)00627-5","article-title":"Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles","volume":"40","author":"Cruz","year":"2003","journal-title":"Neuron"},{"key":"ref_401","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/45159","article-title":"Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration","volume":"402","author":"Patrick","year":"1999","journal-title":"Nature"},{"key":"ref_402","doi-asserted-by":"crossref","first-page":"135453","DOI":"10.1016\/j.neulet.2020.135453","article-title":"Changes in the prefrontal cortex after the hippocampus was injected with A\u03b225-35 via the P35\/P25-CDK5-Tau hyperphosphorylation signaling pathway","volume":"741","author":"Wang","year":"2021","journal-title":"Neurosci. Lett."},{"key":"ref_403","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.neuron.2018.07.039","article-title":"Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer\u2019s Disease","volume":"99","author":"Eftekharzadeh","year":"2018","journal-title":"Neuron"},{"key":"ref_404","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.celrep.2018.12.085","article-title":"Microtubules Deform the Nuclear Membrane and Disrupt Nucleocytoplasmic Transport in Tau-Mediated Frontotemporal Dementia","volume":"26","author":"Paonessa","year":"2019","journal-title":"Cell Rep."},{"key":"ref_405","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fnmol.2014.00036","article-title":"Generation of the Cdk5 activator p25 is a memory mechanism that is affected in early Alzheimer\u2019s disease","volume":"7","author":"Giese","year":"2014","journal-title":"Front. Mol. Neurosci."},{"key":"ref_406","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000074622","article-title":"Role of cdk5 in the pathogenesis of Alzheimer\u2019s disease","volume":"12","author":"Lau","year":"2003","journal-title":"Neurosignals"},{"key":"ref_407","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1007\/s12035-015-9369-x","article-title":"The Role of Cdk5 in Alzheimer\u2019s Disease","volume":"53","author":"Liu","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"ref_408","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.brainresbull.2017.05.006","article-title":"Cyclin dependent kinase 5: A novel avenue for Alzheimer\u2019s disease","volume":"132","author":"Bhounsule","year":"2017","journal-title":"Brain Res. Bull."},{"key":"ref_409","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3233\/JAD-191098","article-title":"Cdk5 Inhibitory Peptide Prevents Loss of Neurons and Alleviates Behavioral Changes in p25 Transgenic Mice","volume":"74","author":"Huang","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"ref_410","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1523\/JNEUROSCI.3593-12.2013","article-title":"Specific inhibition of p25\/Cdk5 activity by the Cdk5 inhibitory peptide reduces neurodegeneration in vivo","volume":"33","author":"Sundaram","year":"2013","journal-title":"J. Neurosci."},{"key":"ref_411","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1096\/fj.201700064R","article-title":"Adeno-associated virus 9-mediated Cdk5 inhibitory peptide reverses pathologic changes and behavioral deficits in the Alzheimer\u2019s disease mouse model","volume":"31","author":"He","year":"2017","journal-title":"FASEB J."},{"key":"ref_412","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3233\/JAD-190099","article-title":"AAV9-Mediated Cdk5 Inhibitory Peptide Reduces Hyperphosphorylated Tau and Inflammation and Ameliorates Behavioral Changes Caused by Overexpression of p25 in the Brain","volume":"70","author":"Xu","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"ref_413","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3233\/JAD-160916","article-title":"TFP5, a Peptide Inhibitor of Aberrant and Hyperactive Cdk5\/p25, Attenuates Pathological Phenotypes and Restores Synaptic Function in CK-p25Tg Mice","volume":"56","author":"Shukla","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"ref_414","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1096\/fj.12-217497","article-title":"A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer\u2019s disease phenotypes in model mice","volume":"27","author":"Shukla","year":"2013","journal-title":"FASEB J."},{"key":"ref_415","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1038\/cddis.2011.2","article-title":"Modulation of aberrant CDK5 signaling rescues impaired neurogenesis in models of Alzheimer\u2019s disease","volume":"2","author":"Crews","year":"2011","journal-title":"Cell Death Dis."},{"key":"ref_416","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.2174\/138161212800672804","article-title":"Cyclin-dependent kinase inhibitors inspired by roscovitine: Purine bioisosteres","volume":"18","author":"Jorda","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"ref_417","doi-asserted-by":"crossref","unstructured":"Chen, J., Li, S., Sun, W., and Li, J. (2015). Anti-diabetes drug pioglitazone ameliorates synaptic defects in AD transgenic mice by inhibiting cyclin-dependent kinase5 activity. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0123864"},{"key":"ref_418","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1517\/14740331003623218","article-title":"Pioglitazone: Side effect and safety profile","volume":"9","author":"Shah","year":"2010","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_419","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ijdevneu.2008.07.016","article-title":"Cell cycle activation in striatal neurons from Huntington\u2019s disease patients and rats treated with 3-nitropropionic acid","volume":"26","author":"Ferrer","year":"2008","journal-title":"Int. J. Dev. Neurosci."},{"key":"ref_420","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.nbd.2010.08.014","article-title":"Impaired ATF6\u03b1 processing, decreased Rheb and neuronal cell cycle re-entry in Huntington\u2019s disease","volume":"41","author":"Ferrer","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"ref_421","first-page":"369","article-title":"Perturbations of cell-cycle progression in gamma-irradiated ataxia telangiectasia and Huntington\u2019s disease cells detected by DNA flow cytometric analysis","volume":"112","author":"Imray","year":"1983","journal-title":"Mutat. Res."},{"key":"ref_422","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/hmg\/ddu574","article-title":"Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington\u2019s disease","volume":"24","author":"Liu","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_423","doi-asserted-by":"crossref","first-page":"6594","DOI":"10.1074\/jbc.M707730200","article-title":"Differential involvement of cell cycle reactivation between striatal and cortical neurons in cell death induced by 3-nitropropionic acid","volume":"283","author":"Akashiba","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_424","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.csbj.2016.02.001","article-title":"Network analysis of human post-mortem microarrays reveals novel genes, microRNAs, and mechanistic scenarios of potential importance in fighting huntington\u2019s disease","volume":"14","author":"Chandrasekaran","year":"2016","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_425","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.neulet.2007.05.038","article-title":"3-Nitropropionic acid activates calpain\/cdk5 pathway in rat striatum","volume":"421","author":"Camins","year":"2007","journal-title":"Neurosci. Lett."},{"key":"ref_426","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1212\/WNL.0b013e3181eccfa2","article-title":"Mild cognitive impairment in prediagnosed Huntington disease","volume":"75","author":"Duff","year":"2010","journal-title":"Neurology"},{"key":"ref_427","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/brain\/121.7.1329","article-title":"Evidence for specific cognitive deficits in preclinical Huntington\u2019s disease","volume":"121","author":"Lawrence","year":"1998","journal-title":"Brain"},{"key":"ref_428","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/brain\/119.5.1633","article-title":"Executive and mnemonic functions in early Huntington\u2019s disease","volume":"119","author":"Lawrence","year":"1996","journal-title":"Brain"},{"key":"ref_429","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1007\/s12035-017-0828-4","article-title":"Cdk5 Contributes to Huntington\u2019s Disease Learning and Memory Deficits via Modulation of Brain Region-Specific Substrates","volume":"55","author":"Brito","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_430","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1037\/a0029218","article-title":"PREDICT-HD Investigators of the Huntington Study Group. Depressive symptom severity is related to poorer cognitive performance in prodromal Huntington disease","volume":"26","author":"Smith","year":"2012","journal-title":"Neuropsychology"},{"key":"ref_431","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/978-981-13-9913-8_14","article-title":"Astrocytes in Huntington\u2019s Disease","volume":"1175","author":"Gray","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_432","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3233\/JHD-2012-129000","article-title":"Decreasing Levels of the cdk5 Activators, p25 and p35, Reduces Excitotoxicity in Striatal Neurons","volume":"1","author":"Park","year":"2012","journal-title":"J. Huntingt. Dis."},{"key":"ref_433","doi-asserted-by":"crossref","first-page":"10116","DOI":"10.1523\/JNEUROSCI.18-23-10116.1998","article-title":"Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington\u2019s disease","volume":"18","author":"Reynolds","year":"1998","journal-title":"J. Neurosci."},{"key":"ref_434","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1083\/jcb.200412071","article-title":"Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: Implications for mutant huntingtin toxicity","volume":"169","author":"Luo","year":"2005","journal-title":"J. Cell Biol."},{"key":"ref_435","doi-asserted-by":"crossref","first-page":"7318","DOI":"10.1523\/JNEUROSCI.1831-07.2007","article-title":"Phosphorylation of huntingtin by cyclin-dependent kinase 5 is induced by DNA damage and regulates wild-type and mutant huntingtin toxicity in neurons","volume":"27","author":"Anne","year":"2007","journal-title":"J. Neurosci."},{"key":"ref_436","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1111\/j.1460-9568.2008.06491.x","article-title":"A chemical compound commonly used to inhibit PKR, {8-(imidazol-4-ylmethylene)-6H-azolidino[5, 4-g] benzothiazol-7-one}, protects neurons by inhibiting cyclin-dependent kinase","volume":"28","author":"Chen","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"ref_437","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bbadis.2009.07.012","article-title":"Mitochondria in Huntington\u2019s disease","volume":"1802","author":"Damiano","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_438","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1172\/JCI70911","article-title":"Inhibition of mitochondrial fragmentation diminishes Huntington\u2019s disease-associated neurodegeneration","volume":"123","author":"Guo","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_439","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.neuroscience.2017.03.051","article-title":"p35 hemizygosity activates Akt but does not improve motor function in the YAC128 mouse model of Huntington\u2019s disease","volume":"352","author":"Park","year":"2017","journal-title":"Neuroscience"},{"key":"ref_440","doi-asserted-by":"crossref","first-page":"8747","DOI":"10.1523\/JNEUROSCI.0973-08.2008","article-title":"Suppression of mutant Huntingtin aggregate formation by Cdk5\/p35 through the effect on microtubule stability","volume":"28","author":"Kaminosono","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_441","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41586-019-1195-2","article-title":"Single-cell transcriptomic analysis of Alzheimer\u2019s disease","volume":"570","author":"Mathys","year":"2019","journal-title":"Nature"},{"key":"ref_442","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41591-019-0695-9","article-title":"Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer\u2019s disease","volume":"26","author":"Zhou","year":"2020","journal-title":"Nat. Med."},{"key":"ref_443","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1474-4422(11)70156-9","article-title":"Neuropathologically defined subtypes of Alzheimer\u2019s disease with distinct clinical characteristics: A retrospective study","volume":"10","author":"Murray","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_444","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41591-021-01309-6","article-title":"Four distinct trajectories of tau deposition identified in Alzheimer\u2019s disease","volume":"27","author":"Vogel","year":"2021","journal-title":"Nat. Med."},{"key":"ref_445","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pneurobio.2018.07.004","article-title":"Oligodendrogliopathy in neurodegenerative diseases with abnormal protein aggregates: The forgotten partner","volume":"169","author":"Ferrer","year":"2018","journal-title":"Prog. Neurobiol."},{"key":"ref_446","doi-asserted-by":"crossref","first-page":"10049","DOI":"10.1038\/s41598-019-46454-8","article-title":"Identification of GSK3\u03b2 inhibitor kenpaullone as a temozolomide enhancer against glioblastoma","volume":"9","author":"Kitabayashi","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_447","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.cellsig.2008.12.008","article-title":"Reduced amyloidogenic processing of the amyloid beta-protein precursor by the small-molecule Differentiation Inducing Factor-1","volume":"21","author":"Myre","year":"2009","journal-title":"Cell Signal."},{"key":"ref_448","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1021\/mp100179t","article-title":"Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machines","volume":"7","author":"Ma","year":"2010","journal-title":"Mol. Pharm."},{"key":"ref_449","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.ejmech.2007.09.020","article-title":"Novel 9-oxo-thiazolo[5, 4-f]quinazoline-2-carbonitrile derivatives as dual cyclin-dependent kinase 1 (CDK1)\/glycogen synthase kinase-3 (GSK-3) inhibitors: Synthesis, biological evaluation and molecular modeling studies","volume":"43","author":"Testard","year":"2008","journal-title":"Eur. J. Med. Chem."},{"key":"ref_450","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1158\/0008-5472.CAN-11-1383","article-title":"Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3\u03b2 and CDK1","volume":"71","author":"Mayes","year":"2011","journal-title":"Cancer Res."},{"key":"ref_451","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1021\/jm0308904","article-title":"Evaluation and comparison of 3D-QSAR CoMSIA models for CDK1, CDK5, and GSK-3 inhibition by paullones","volume":"47","author":"Kunick","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_452","doi-asserted-by":"crossref","first-page":"6914","DOI":"10.1016\/j.bmcl.2012.09.006","article-title":"Multitargeted drug development: Discovery and profiling of dihydroxy substituted 1-aza-9-oxafluorenes as lead compounds targeting Alzheimer disease relevant kinases","volume":"22","author":"Tell","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_453","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/S0968-0896(02)00069-X","article-title":"Pyrazolo[3, 4-b]quinoxalines. A new class of cyclin-dependent kinases inhibitors","volume":"10","author":"Ortega","year":"2002","journal-title":"Bioorg. Med. Chem."},{"key":"ref_454","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1021\/jm020319p","article-title":"Aloisines, a new family of CDK\/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects","volume":"46","author":"Mettey","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_455","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ejmech.2019.04.035","article-title":"Pyridinylimidazoles as dual glycogen synthase kinase 3\u03b2\/p38\u03b1 mitogen-activated protein kinase inhibitors","volume":"175","author":"Heider","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_456","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ejmech.2016.02.072","article-title":"Novel optimization of valmerins (tetrahydropyrido[1,8 2-a]isoindolones) as potent dual CDK5\/GSK3 inhibitors","volume":"115","author":"Ouach","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_457","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1007\/s00894-014-2407-1","article-title":"Structural basis of valmerins as dual inhibitors of GSK3\u03b2\/CDK5","volume":"20","author":"Li","year":"2014","journal-title":"J. Mol. Model."},{"key":"ref_458","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.stemcr.2019.01.015","article-title":"Dual Inhibition of GSK3\u03b2 and CDK5 Protects the Cytoskeleton of Neurons from Neuroinflammatory-Mediated Degeneration In Vitro and In Vivo","volume":"12","author":"Reinhardt","year":"2019","journal-title":"Stem Cell Rep."},{"key":"ref_459","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1002\/jnr.22352","article-title":"Identification of novel 1, 4-benzoxazine compounds that are protective in tissue culture and in vivo models of neurodegeneration","volume":"88","author":"Wang","year":"2010","journal-title":"J. Neurosci. Res."},{"key":"ref_460","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1159\/000485008","article-title":"Roscovitine, a CDK5 Inhibitor, Alleviates Sevoflurane-Induced Cognitive Dysfunction via Regulation Tau\/GSK3\u03b2 and ERK\/PPAR\u03b3\/CREB Signaling","volume":"44","author":"Liu","year":"2017","journal-title":"Cell Physiol. Biochem."},{"key":"ref_461","doi-asserted-by":"crossref","first-page":"E4887","DOI":"10.1073\/pnas.1402627111","article-title":"CDK5 activator protein p25 preferentially binds and activates GSK3\u03b2","volume":"111","author":"Chow","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_462","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2174\/1389450110607011377","article-title":"Glycogen synthase kinase-3-an overview of an over-achieving protein kinase","volume":"7","author":"Kockeritz","year":"2006","journal-title":"Curr. Drug Targets."},{"key":"ref_463","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/BF02787342","article-title":"Cancer morbidity in psychiatric patients: Influence of lithium carbonate treatment","volume":"15","author":"Cohen","year":"1998","journal-title":"Med. Oncol."},{"key":"ref_464","doi-asserted-by":"crossref","unstructured":"Salman, M.M., Al-Obaidi, Z., Kitchen, P., Loreto, A., Bill, R.M., and Wade-Martins, R. (2021). Advances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094688"},{"key":"ref_465","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2174\/1570159X15666170823095628","article-title":"In Silico Studies in Drug Research Against Neurodegenerative Diseases","volume":"16","author":"Makhouri","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"ref_466","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.2174\/1381612824666180607124038","article-title":"Machine Learning-based Virtual Screening and Its Applications to Alzheimer\u2019s Drug Discovery: A Review","volume":"24","author":"Carpenter","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"ref_467","doi-asserted-by":"crossref","unstructured":"Aldewachi, H., Al-Zidan, R.N., Conner, M.T., and Salman, M.M. (2021). High-Throughput Screening Platforms in the Discovery of Novel Drugs for Neurodegenerative Diseases. Bioengineering, 8.","DOI":"10.3390\/bioengineering8020030"},{"key":"ref_468","unstructured":"Lo, D.C., and Hughes, R.E. (2021, May 20). High-Throughput and High-Content Screening for Huntington\u2019s Disease Therapeutics, Neurobiology of Huntington\u2019s Disease: Applications to Drug Discovery, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK55989\/."},{"key":"ref_469","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/j.ddtec.2012.02.002","article-title":"Alzheimer\u2019s disease drug discovery: In vivo screening using Caenorhabditis elegans as a model for \u03b2-amyloid peptide-induced toxicity","volume":"10","author":"Lublin","year":"2013","journal-title":"Drug Discov. Today Technol."},{"key":"ref_470","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12929-017-0362-8","article-title":"3D brain Organoids derived from pluripotent stem cells: Promising experimental models for brain development and neurodegenerative disorders","volume":"24","author":"Lee","year":"2017","journal-title":"J. Biomed. Sci."},{"key":"ref_471","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13024-016-0139-7","article-title":"3D culture models of Alzheimer\u2019s disease: A road map to a \u201ccure-in-a-dish.\u201d","volume":"11","author":"Choi","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"ref_472","doi-asserted-by":"crossref","unstructured":"Kumar, A., Zhou, L., Zhi, K., Raji, B., Pernell, S., Tadrous, E., Kodidela, S., Nookala, A., Kochat, H., and Kumar, S. (2020). Challenges in Biomaterial-Based Drug Delivery Approach for the Treatment of Neurodegenerative Diseases: Opportunities for Extracellular Vesicles. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010138"},{"key":"ref_473","doi-asserted-by":"crossref","first-page":"e1153568","DOI":"10.1080\/21688370.2016.1153568","article-title":"Nanoparticle transport across the blood brain barrier","volume":"4","author":"Grabrucker","year":"2016","journal-title":"Tissue Barriers"},{"key":"ref_474","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/10717544.2018.1428243","article-title":"Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer\u2019s disease","volume":"25","author":"Karthivashan","year":"2018","journal-title":"Drug Deliv."},{"key":"ref_475","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jconrel.2019.10.007","article-title":"MicroRNA delivery through nanoparticles","volume":"313","author":"Lee","year":"2019","journal-title":"J. Control Release"},{"key":"ref_476","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejpb.2019.12.014","article-title":"Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer\u2019s disease","volume":"148","author":"Akel","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_477","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/17425247.2018.1429401","article-title":"Lipid nanoparticles for intranasal administration: Application to nose-to-brain delivery","volume":"15","author":"Battaglia","year":"2018","journal-title":"Expert Opin. Drug Deliv."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/11\/5911\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:09:26Z","timestamp":1760162966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/11\/5911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":477,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["ijms22115911"],"URL":"https:\/\/doi.org\/10.3390\/ijms22115911","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,31]]}}}